Released Aug 9, 2018, before the open
10-Q filed Aug 9, 2018, 40 days after period end · 0001144204-18-043286
Q2 2018 · 10-Q
Revenue$2.01M$2.01M −68.4% vs Q2 2017−55.9% vs Q1 2018
Net Income-$8.46M-$8.46M N/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$0.06-$0.06 N/M vs Q2 2017N/M vs Q1 2018
Gross Profit-$177,000N/M
Operating Income-$6,744,000N/M
Operating Cash Flowderived-$7,964,000N/M
Free Cash Flowderived-$8,109,000N/M
Margins · derived
Gross margin-8.8%−22.0 pt vs Q2 2017
Operating margin-336.2%−166.2 pt vs Q2 2017
Net margin-421.8%−428.9 pt vs Q2 2017
What the release said
The release
Same quarter
| Metric | Q2 2018 | Q2 2017 | Q2 2016 | Q2 2015 |
|---|---|---|---|---|
| Revenue | $2.01M | $6.36M | $1.77M | $1.34M |
| Net Income | -$8.46M | $450.00K | -$10.85M | -$5.07M |
| EPS Diluted | -$0.06 | -$0.06 | -$0.11 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR